Tammy Gillett
Women's Health · Kinder, LANPI 1962401265
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,337 of the $2,626 with a category attached, or 89.0%. 27 manufacturers reported payments, led by AbbVie at 28.2% of the total.
Across 151 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$740
- Astellas Pharma US Inc$373
- Axsome Therapeutics, Inc.$257
- Evofem Biosciences, Inc.$237
- Sumitomo Pharma America, Inc.$174
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$153
- plus $692 from 21 others
What the payments were for
- Food & beverage$2,33789%
- Education$28911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$2,626 in reported general payments places this provider in the 85th percentile of 128 women's health providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 29 | $15,783 |
| OzempicSemaglutide | 14 | $14,671 |
| EliquisApixaban | 13 | $14,265 |
| FarxigaDapagliflozin Propanediol | 13 | $8,255 |
| Estradiol | 111 | $7,426 |
| TradjentaLinagliptin | 12 | $6,278 |
| TrintellixVortioxetine Hydrobromide | 13 | $5,988 |
| Gabapentin | 109 | $1,460 |
| Pregabalin | 26 | $1,401 |
| YuvafemEstradiol | 16 | $789 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 51 | $581 |
| Vilazodone Hcl | 14 | $429 |
| Montelukast Sodium | 70 | $428 |
| Bisoprolol-HydrochlorothiazideBisoprolol/Hydrochlorothiazide | 17 | $412 |
| Levothyroxine Sodium | 49 | $277 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $373 | $15,78329 claims |
| Novo NordiskOzempic | $33 | $14,67114 claims |
| PfizerEliquis | $16 | $14,26513 claims |
| AstraZenecaFarxiga | $29 | $8,25513 claims |
| Boehringer IngelheimTradjenta | $16 | $6,27812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 128 women's health providers in Louisiana.
Other women's health in Kinder
- Amanda HayesShreveport$51K
- Nancy WellsBossier City$47K
- Ann JoplingMonroe$16K
- Kendra Joseph-RodgersNew Orleans$10K
- Aundria CannonLafayette$5K
- Jordan ForsthoffLafayette$5K
- Jennifer MillerMonroe$4K
- Alysha HinsonShreveport$4K
- Christie WaltersMonroe$4K
- Kristen MuhoberacMetairie$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.